These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. Pillai S; Gopalan V; Smith RA; Lam AK Crit Rev Oncol Hematol; 2015 Apr; 94(1):64-73. PubMed ID: 25577570 [TBL] [Abstract][Full Text] [Related]
3. Prognostic importance of solid variant papillary thyroid carcinoma: A systematic review and meta-analysis. Vuong HG; Odate T; Duong UNP; Mochizuki K; Nakazawa T; Katoh R; Kondo T Head Neck; 2018 Jul; 40(7):1588-1597. PubMed ID: 29509280 [TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of Muc1, p63 protein in diffuse sclerosing variant of papillary thyroid carcinoma and conventional papillary thyroid carcinoma]. Hao Y; Jin C; Wang J Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 May; 27(9):457-61. PubMed ID: 23898609 [TBL] [Abstract][Full Text] [Related]
5. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894 [TBL] [Abstract][Full Text] [Related]
6. Outcome of the Diffuse Sclerosing Variant of Papillary Thyroid Cancer: A Meta-Analysis. Malandrino P; Russo M; Regalbuto C; Pellegriti G; Moleti M; Caff A; Squatrito S; Vigneri R Thyroid; 2016 Sep; 26(9):1285-92. PubMed ID: 27349273 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis. Liu Z; Zeng W; Chen T; Guo Y; Zhang C; Liu C; Huang T Oncotarget; 2017 Jan; 8(4):6222-6232. PubMed ID: 28009980 [TBL] [Abstract][Full Text] [Related]
8. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma? Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289 [TBL] [Abstract][Full Text] [Related]
9. Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study. Chereau N; Giudicelli X; Pattou F; Lifante JC; Triponez F; Mirallié E; Goudet P; Brunaud L; Trésallet C; Tissier F; Leenhardt L; du Montcel ST; Menegaux F J Clin Endocrinol Metab; 2016 Dec; 101(12):4603-4610. PubMed ID: 27626975 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and prognostic factors of tall cell variant of papillary thyroid carcinoma: comparison with classic variant of papillary thyroid carcinoma. Okuyucu K; Alagoz E; Arslan N; Emer O; Ince S; Deveci S; Ayan A; Taslipinar A; Gunalp B; Azal O Nucl Med Commun; 2015 Oct; 36(10):1021-5. PubMed ID: 26225942 [TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Wu MH; Shen WT; Gosnell J; Duh QY Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456 [TBL] [Abstract][Full Text] [Related]
12. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer. Wang C; Chen X; Wei X; Chen F; Wang Y; Shen Z Asian J Surg; 2017 Jan; 40(1):55-60. PubMed ID: 27697309 [TBL] [Abstract][Full Text] [Related]
13. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Regalbuto C; Malandrino P; Tumminia A; Le Moli R; Vigneri R; Pezzino V Thyroid; 2011 Apr; 21(4):383-9. PubMed ID: 21309722 [TBL] [Abstract][Full Text] [Related]
14. A Meta-analysis of Central Lymph Node Metastasis for Predicting Lateral Involvement in Papillary Thyroid Carcinoma. Lan X; Sun W; Zhang H; Dong W; Wang Z; Zhang T Otolaryngol Head Neck Surg; 2015 Nov; 153(5):731-8. PubMed ID: 26307575 [TBL] [Abstract][Full Text] [Related]
15. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients. Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: A meta-analysis. Yan B; Hou Y; Chen D; He J; Jiang Y Int J Surg; 2018 Nov; 59():90-98. PubMed ID: 30342280 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Wang W; Su X; He K; Wang Y; Wang H; Wang H; Zhao Y; Zhao W; Zarnegar R; Fahey TJ; Teng X; Teng L Cancer; 2016 Jan; 122(2):198-206. PubMed ID: 26506214 [TBL] [Abstract][Full Text] [Related]
19. Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Jin BJ; Kim MK; Ji YB; Song CM; Park JH; Tae K Oral Oncol; 2015 Aug; 51(8):759-63. PubMed ID: 26093388 [TBL] [Abstract][Full Text] [Related]
20. Bilaterality weighs more than unilateral multifocality in predicting prognosis in papillary thyroid cancer. Qu N; Zhang L; Wu WL; Ji QH; Lu ZW; Zhu YX; Lin DZ Tumour Biol; 2016 Jul; 37(7):8783-9. PubMed ID: 26743781 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]